

Shohreh Shahabi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/43708/publications.pdf>

Version: 2024-02-01

41
papers

990
citations

471509

17
h-index

454955

30
g-index

41
all docs

41
docs citations

41
times ranked

1797
citing authors

#	ARTICLE	IF	CITATIONS
1	Feasibility and Preliminary Efficacy of a Bright Light Intervention in Ovarian and Endometrial Cancer Survivors. <i>International Journal of Behavioral Medicine</i> , 2021, 28, 83-95.	1.7	12
2	Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trial. <i>Gynecologic Oncology</i> , 2021, 163, 57-63.	1.4	6
3	How Can Pelvic MRI with Diffusion-Weighted Imaging Help My Pregnant Patient?. <i>American Journal of Perinatology</i> , 2020, 37, 577-588.	1.4	10
4	Association between Cervical Dysplasia and Adverse Pregnancy Outcomes. <i>American Journal of Perinatology</i> , 2020, 37, 947-954.	1.4	1
5	Further content validation of the 18-item NCCN/FACT Ovarian Symptom Index and its Disease Related Symptom-Physical (DRS-P) subscale for use in advanced ovarian cancer clinical trials. <i>Health and Quality of Life Outcomes</i> , 2019, 17, 185.	2.4	5
6	Association of chemotherapy and radiotherapy sequence with overall survival in locoregionally advanced endometrial cancer. <i>Gynecologic Oncology</i> , 2019, 153, 41-48.	1.4	29
7	Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5538-5538.	1.6	3
8	The selected biomarker analysis in 5 types of uterine smooth muscle tumors. <i>Human Pathology</i> , 2018, 76, 17-27.	2.0	21
9	Prognosis and treatment of positive peritoneal cytology in early endometrial cancer: matched cohort analyses from the National Cancer Database. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 218, 329.e1-329.e15.	1.3	61
10	Association of Circulating Tumor Cell Status With Benefit of Radiotherapy and Survival in Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, e180163.	7.1	105
11	21-Gene Recurrence Score Assay Predicts Benefit of Post-Mastectomy Radiotherapy in T1-2 N1 Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 3878-3887.	7.0	34
12	Discussing sarcoma risks during informed consent for nonhysterectomy management of fibroids: an unmet need. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 218, 103.e1-103.e5.	1.3	7
13	Scholarship Support for Veterans Enrolling in MD, JD, and MBA Programs. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1197.	7.4	1
14	Increased HE4 mRNA Expression Correlates with High Level Of eIF3a mRNA And Better Survival in Women with Epithelial Ovarian Cancer. <i>Journal of Cancer</i> , 2018, 9, 1088-1095.	2.5	7
15	HE4 and eIF3a Expression Correlates with Surgical Outcome and Overall Survival in Ovarian Cancer Patients with Secondary Cytoreduction. <i>Journal of Cancer</i> , 2018, 9, 2472-2479.	2.5	4
16	Outcomes and costs of open, robotic, and laparoscopic radical hysterectomy for stage IB1 cervical cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5502-5502.	1.6	24
17	Association of increased primary breast tumor AGR2 with decreased disease-specific survival. <i>Oncotarget</i> , 2018, 9, 23114-23125.	1.8	11
18	Cost-effectiveness analysis of dose-dense versus standard intravenous chemotherapy for ovarian cancer: An economic analysis of results from the Gynecologic Oncology Group protocol 262 randomized controlled trial. <i>Gynecologic Oncology</i> , 2017, 145, 9-14.	1.4	10

#	ARTICLE	IF	CITATIONS
19	Chemotherapy delay after primary debulking surgery for ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 144, 260-265.	1.4	36
20	Ovarian granulosa cell tumor: A National Cancer Database study. <i>Gynecologic Oncology</i> , 2017, 146, 285-291.	1.4	74
21	Low-grade and high-grade endometrial stromal sarcoma: A National Cancer Database study. <i>Gynecologic Oncology</i> , 2017, 146, 254-262.	1.4	83
22	Stage I uterine carcinosarcoma: Matched cohort analyses for lymphadenectomy, chemotherapy, and brachytherapy. <i>Gynecologic Oncology</i> , 2017, 145, 71-77.	1.4	24
23	Prognosis and treatment of uterine leiomyosarcoma: A National Cancer Database study. <i>Gynecologic Oncology</i> , 2017, 145, 61-70.	1.4	144
24	Macrogenomic engineering via modulation of the scaling of chromatin packing density. <i>Nature Biomedical Engineering</i> , 2017, 1, 902-913.	22.5	47
25	The Hispanic Paradox in endometrial cancer: A National Cancer Database study. <i>Gynecologic Oncology</i> , 2017, 146, 351-358.	1.4	10
26	Transversus abdominis plane block with liposomal bupivacaine compared to oral opioids alone for acute postoperative pain after laparoscopic hysterectomy for early endometrial cancer: a cost-effectiveness analysis. <i>Gynecologic Oncology Research and Practice</i> , 2017, 4, 12.	3.6	7
27	Survival Disparities by Hospital Volume Among American Women With Gynecologic Cancers. <i>JCO Clinical Cancer Informatics</i> , 2017, 1, 1-15.	2.1	10
28	Association of Lymph Node Count and Overall Survival in Node-Negative Endometrial Cancers. <i>JCO Clinical Cancer Informatics</i> , 2017, 1, 1-15.	2.1	1
29	Circulating tumor cell status and benefit of radiotherapy in stage I breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11524-11524.	1.6	0
30	Examining screening behaviors at a high-risk ovarian cancer clinic.. <i>Journal of Clinical Oncology</i> , 2017, 35, e13047-e13047.	1.6	0
31	Surgical wait time: A new health indicator in women with endometrial cancer. <i>Gynecologic Oncology</i> , 2016, 141, 511-515.	1.4	45
32	Survival of women with Mullerian adenosarcoma: A National Cancer Data Base study. <i>Gynecologic Oncology</i> , 2016, 143, 636-641.	1.4	44
33	Discovery of candidate tumor biomarkers for treatment with intraperitoneal chemotherapy for ovarian cancer. <i>Scientific Reports</i> , 2016, 6, 21591.	3.3	18
34	Survival after pelvic exenteration for uterine malignancy: A National Cancer Data Base study. <i>Gynecologic Oncology</i> , 2016, 143, 472-478.	1.4	19
35	Elimination of pelvic exams in a high-risk ovarian cancer screening program.. <i>Journal of Clinical Oncology</i> , 2016, 34, e13059-e13059.	1.6	1
36	Urine Protein/Creatinine Ratios during Labor: A Prospective Observational Study. <i>PLoS ONE</i> , 2016, 11, e0160453.	2.5	7

#	ARTICLE	IF	CITATIONS
37	Use of adjuvant chemotherapy and radiation in women with node-positive endometrial cancer: A National Cancer Database study.. Journal of Clinical Oncology, 2016, 34, 5588-5588.	1.6	0
38	Delayed and clinically isolated port site carcinosarcoma recurrence as an early indicator of disseminated disease. Gynecologic Oncology Reports, 2015, 14, 12-15.	0.6	4
39	Metastatic Uterine Leiomyosarcoma Involving Bilateral Ovarian Stroma without Capsular Involvement Implies a Local Route of Hematogenous Dissemination. Case Reports in Obstetrics and Gynecology, 2015, 2015, 1-5.	0.3	4
40	The impact of international economic sanctions on Iranian cancer healthcare. Health Policy, 2015, 119, 1309-1318.	3.0	41
41	Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers. Oncotarget, 2015, 6, 18641-18652.	1.8	20